Bill Text: IL HB2534 | 2017-2018 | 100th General Assembly | Engrossed


Bill Title: Amends the Illinois Controlled Substances Act. Requires that to be illegal a drug analog must not be approved by the United States Food and Drug Administration or, if approved, it is not dispensed or possessed in accordance with State and federal law. Defines "controlled substance" to include a synthetic drug enumerated as a scheduled drug under the Act. Adds chemical structural classes of synthetic cannabinoids and piperazines to the list of Schedule I controlled substances. Includes certain substances approved by the FDA which are not dispensed or possessed in accordance with State or federal law and certain modified substances.

Spectrum: Slight Partisan Bill (Republican 35-18)

Status: (Engrossed) 2017-04-26 - Added as Alternate Co-Sponsor Sen. Kimberly A. Lightford [HB2534 Detail]

Download: Illinois-2017-HB2534-Engrossed.html



HB2534 EngrossedLRB100 08419 RLC 18533 b
1 AN ACT concerning criminal law.
2 Be it enacted by the People of the State of Illinois,
3represented in the General Assembly:
4 Section 5. The Illinois Controlled Substances Act is
5amended by changing Sections 204, 206, 208, 401, and 402 as
6follows:
7 (720 ILCS 570/204) (from Ch. 56 1/2, par. 1204)
8 Sec. 204. (a) The controlled substances listed in this
9Section are included in Schedule I.
10 (b) Unless specifically excepted or unless listed in
11another schedule, any of the following opiates, including their
12isomers, esters, ethers, salts, and salts of isomers, esters,
13and ethers, whenever the existence of such isomers, esters,
14ethers and salts is possible within the specific chemical
15designation:
16 (1) Acetylmethadol;
17 (1.1) Acetyl-alpha-methylfentanyl
18 (N-[1-(1-methyl-2-phenethyl)-
19 4-piperidinyl]-N-phenylacetamide);
20 (2) Allylprodine;
21 (3) Alphacetylmethadol, except
22 levo-alphacetylmethadol (also known as levo-alpha-
23 acetylmethadol, levomethadyl acetate, or LAAM);

HB2534 Engrossed- 2 -LRB100 08419 RLC 18533 b
1 (4) Alphameprodine;
2 (5) Alphamethadol;
3 (6) Alpha-methylfentanyl
4 (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
5 propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
6 propanilido) piperidine;
7 (6.1) Alpha-methylthiofentanyl
8 (N-[1-methyl-2-(2-thienyl)ethyl-
9 4-piperidinyl]-N-phenylpropanamide);
10 (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);
11 (7.1) PEPAP
12 (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
13 (8) Benzethidine;
14 (9) Betacetylmethadol;
15 (9.1) Beta-hydroxyfentanyl
16 (N-[1-(2-hydroxy-2-phenethyl)-
17 4-piperidinyl]-N-phenylpropanamide);
18 (10) Betameprodine;
19 (11) Betamethadol;
20 (12) Betaprodine;
21 (13) Clonitazene;
22 (14) Dextromoramide;
23 (15) Diampromide;
24 (16) Diethylthiambutene;
25 (17) Difenoxin;
26 (18) Dimenoxadol;

HB2534 Engrossed- 3 -LRB100 08419 RLC 18533 b
1 (19) Dimepheptanol;
2 (20) Dimethylthiambutene;
3 (21) Dioxaphetylbutyrate;
4 (22) Dipipanone;
5 (23) Ethylmethylthiambutene;
6 (24) Etonitazene;
7 (25) Etoxeridine;
8 (26) Furethidine;
9 (27) Hydroxpethidine;
10 (28) Ketobemidone;
11 (29) Levomoramide;
12 (30) Levophenacylmorphan;
13 (31) 3-Methylfentanyl
14 (N-[3-methyl-1-(2-phenylethyl)-
15 4-piperidyl]-N-phenylpropanamide);
16 (31.1) 3-Methylthiofentanyl
17 (N-[(3-methyl-1-(2-thienyl)ethyl-
18 4-piperidinyl]-N-phenylpropanamide);
19 (32) Morpheridine;
20 (33) Noracymethadol;
21 (34) Norlevorphanol;
22 (35) Normethadone;
23 (36) Norpipanone;
24 (36.1) Para-fluorofentanyl
25 (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
26 4-piperidinyl]propanamide);

HB2534 Engrossed- 4 -LRB100 08419 RLC 18533 b
1 (37) Phenadoxone;
2 (38) Phenampromide;
3 (39) Phenomorphan;
4 (40) Phenoperidine;
5 (41) Piritramide;
6 (42) Proheptazine;
7 (43) Properidine;
8 (44) Propiram;
9 (45) Racemoramide;
10 (45.1) Thiofentanyl
11 (N-phenyl-N-[1-(2-thienyl)ethyl-
12 4-piperidinyl]-propanamide);
13 (46) Tilidine;
14 (47) Trimeperidine;
15 (48) Beta-hydroxy-3-methylfentanyl (other name:
16 N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
17 N-phenylpropanamide); .
18 (49) Furanyl fentanyl (FU-F);
19 (50) Butyryl fentanyl;
20 (51) Valeryl fentanyl;
21 (52) Acetyl fentanyl;
22 (53) Beta-hydroxy-thiofentanyl;
23 (54) 3,4-dichloro-N-[2-
24 (dimethylamino)cyclohexyl]-N-
25 methylbenzamide (U-47700);
26 (55) 4-chloro-N-[1-[2-

HB2534 Engrossed- 5 -LRB100 08419 RLC 18533 b
1 (4-nitrophenyl)ethyl]-2-piperidinylidene]-
2 benzenesulfonamide (W-18);
3 (56) 4-chloro-N-[1-(2-phenylethyl)
4 -2-piperidinylidene]-benzenesulfonamide (W-15);
5 (57) acrylfentanyl (acryloylfentanyl).
6 (c) Unless specifically excepted or unless listed in
7another schedule, any of the following opium derivatives, its
8salts, isomers and salts of isomers, whenever the existence of
9such salts, isomers and salts of isomers is possible within the
10specific chemical designation:
11 (1) Acetorphine;
12 (2) Acetyldihydrocodeine;
13 (3) Benzylmorphine;
14 (4) Codeine methylbromide;
15 (5) Codeine-N-Oxide;
16 (6) Cyprenorphine;
17 (7) Desomorphine;
18 (8) Diacetyldihydromorphine (Dihydroheroin);
19 (9) Dihydromorphine;
20 (10) Drotebanol;
21 (11) Etorphine (except hydrochloride salt);
22 (12) Heroin;
23 (13) Hydromorphinol;
24 (14) Methyldesorphine;
25 (15) Methyldihydromorphine;
26 (16) Morphine methylbromide;

HB2534 Engrossed- 6 -LRB100 08419 RLC 18533 b
1 (17) Morphine methylsulfonate;
2 (18) Morphine-N-Oxide;
3 (19) Myrophine;
4 (20) Nicocodeine;
5 (21) Nicomorphine;
6 (22) Normorphine;
7 (23) Pholcodine;
8 (24) Thebacon.
9 (d) Unless specifically excepted or unless listed in
10another schedule, any material, compound, mixture, or
11preparation which contains any quantity of the following
12hallucinogenic substances, or which contains any of its salts,
13isomers and salts of isomers, whenever the existence of such
14salts, isomers, and salts of isomers is possible within the
15specific chemical designation (for the purposes of this
16paragraph only, the term "isomer" includes the optical,
17position and geometric isomers):
18 (1) 3,4-methylenedioxyamphetamine
19 (alpha-methyl,3,4-methylenedioxyphenethylamine,
20 methylenedioxyamphetamine, MDA);
21 (1.1) Alpha-ethyltryptamine
22 (some trade or other names: etryptamine;
23 MONASE; alpha-ethyl-1H-indole-3-ethanamine;
24 3-(2-aminobutyl)indole; a-ET; and AET);
25 (2) 3,4-methylenedioxymethamphetamine (MDMA);
26 (2.1) 3,4-methylenedioxy-N-ethylamphetamine

HB2534 Engrossed- 7 -LRB100 08419 RLC 18533 b
1 (also known as: N-ethyl-alpha-methyl-
2 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
3 and MDEA);
4 (2.2) N-Benzylpiperazine (BZP);
5 (2.2-1) Trifluoromethylphenylpiperazine (TFMPP);
6 (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);
7 (4) 3,4,5-trimethoxyamphetamine (TMA);
8 (5) (Blank);
9 (6) Diethyltryptamine (DET);
10 (7) Dimethyltryptamine (DMT);
11 (7.1) 5-Methoxy-diallyltryptamine;
12 (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);
13 (9) Ibogaine (some trade and other names:
14 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
15 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
16 indole; Tabernanthe iboga);
17 (10) Lysergic acid diethylamide;
18 (10.1) Salvinorin A;
19 (10.5) Salvia divinorum (meaning all parts of the plant
20 presently classified botanically as Salvia divinorum,
21 whether growing or not, the seeds thereof, any extract from
22 any part of that plant, and every compound, manufacture,
23 salts, isomers, and salts of isomers whenever the existence
24 of such salts, isomers, and salts of isomers is possible
25 within the specific chemical designation, derivative,
26 mixture, or preparation of that plant, its seeds or

HB2534 Engrossed- 8 -LRB100 08419 RLC 18533 b
1 extracts);
2 (11) 3,4,5-trimethoxyphenethylamine (Mescaline);
3 (12) Peyote (meaning all parts of the plant presently
4 classified botanically as Lophophora williamsii Lemaire,
5 whether growing or not, the seeds thereof, any extract from
6 any part of that plant, and every compound, manufacture,
7 salts, derivative, mixture, or preparation of that plant,
8 its seeds or extracts);
9 (13) N-ethyl-3-piperidyl benzilate (JB 318);
10 (14) N-methyl-3-piperidyl benzilate;
11 (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
12 (also known as N-hydroxy-alpha-methyl-
13 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);
14 (15) Parahexyl; some trade or other names:
15 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
16 dibenzo (b,d) pyran; Synhexyl;
17 (16) Psilocybin;
18 (17) Psilocyn;
19 (18) Alpha-methyltryptamine (AMT);
20 (19) 2,5-dimethoxyamphetamine
21 (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);
22 (20) 4-bromo-2,5-dimethoxyamphetamine
23 (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
24 4-bromo-2,5-DMA);
25 (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
26 Some trade or other names: 2-(4-bromo-

HB2534 Engrossed- 9 -LRB100 08419 RLC 18533 b
1 2,5-dimethoxyphenyl)-1-aminoethane;
2 alpha-desmethyl DOB, 2CB, Nexus;
3 (21) 4-methoxyamphetamine
4 (4-methoxy-alpha-methylphenethylamine;
5 paramethoxyamphetamine; PMA);
6 (22) (Blank);
7 (23) Ethylamine analog of phencyclidine.
8 Some trade or other names:
9 N-ethyl-1-phenylcyclohexylamine,
10 (1-phenylcyclohexyl) ethylamine,
11 N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;
12 (24) Pyrrolidine analog of phencyclidine. Some trade
13 or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy,
14 PHP;
15 (25) 5-methoxy-3,4-methylenedioxy-amphetamine;
16 (26) 2,5-dimethoxy-4-ethylamphetamine
17 (another name: DOET);
18 (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
19 (another name: TCPy);
20 (28) (Blank);
21 (29) Thiophene analog of phencyclidine (some trade
22 or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
23 2-thienyl analog of phencyclidine; TPCP; TCP);
24 (29.1) Benzothiophene analog of phencyclidine Some
25 trade or other names: BTCP or benocyclidine;
26 (29.2) 3-Methoxyphencyclidine (3-MeO-PCP);

HB2534 Engrossed- 10 -LRB100 08419 RLC 18533 b
1 (30) Bufotenine (some trade or other names:
2 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
3 3-(2-dimethylaminoethyl)-5-indolol;
4 5-hydroxy-N,N-dimethyltryptamine;
5 N,N-dimethylserotonin; mappine);
6 (31) (Blank); 1-Pentyl-3-(1-naphthoyl)indole
7 Some trade or other names: JWH-018;
8 (32) (Blank); 1-Butyl-3-(1-naphthoyl)indole
9 Some trade or other names: JWH-073;
10 (33) (Blank); 1-[(5-fluoropentyl)-1H-indol-3-yl]-
11 (2-iodophenyl)methanone
12 Some trade or other names: AM-694;
13 (34) (Blank); 2-[(1R,3S)-3-hydroxycyclohexyl]-5-
14 (2-methyloctan-2-yl)phenol
15 Some trade or other names: CP 47,497
16 and its C6, C8 and C9 homologs;
17 (34.5) (Blank); 2-[(1R,3S)-3-hydroxycyclohexyl]-5-
18 (2-methyloctan-2-yl)phenol), where side chain n=5;
19 and homologues where side chain n=4, 6, or 7; Some
20 trade or other names: CP 47,497;
21 (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-
22 (2-methyloctan-2-yl)-6a,7,
23 10,10a-tetrahydrobenzo[c]chromen-1-ol
24 Some trade or other names: HU-210;
25 (35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6-
26 dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-

HB2534 Engrossed- 11 -LRB100 08419 RLC 18533 b
1 tetrahydrobenzo[c]chromen-1-ol, its isomers,
2 salts, and salts of isomers; Some trade or other
3 names: HU-210, Dexanabinol;
4 (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-
5 6,6-dimethyl-3-(2-methyloctan-2-yl)-
6 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
7 Some trade or other names: HU-211;
8 (37) (Blank); (2-methyl-1-propyl-1H-indol-
9 3-yl)-1-naphthalenyl-methanone
10 Some trade or other names: JWH-015;
11 (38) (Blank); 4-methoxynaphthalen-1-yl-
12 (1-pentylindol-3-yl)methanone
13 Some trade or other names: JWH-081;
14 (39) (Blank); 1-Pentyl-3-(4-methyl-1-naphthoyl)indole
15 Some trade or other names: JWH-122;
16 (40) (Blank); 2-(2-methylphenyl)-1-(1-pentyl-
17 1H-indol-3-yl)-ethanone
18 Some trade or other names: JWH-251;
19 (41) (Blank); 1-(2-cyclohexylethyl)-3-
20 (2-methoxyphenylacetyl)indole
21 Some trade or other names: RCS-8, BTW-8 and SR-18;
22 (42) Any compound structurally derived from
23 3-(1-naphthoyl)indole or 1H-indol-3-yl-
24 (1-naphthyl)methane by substitution at the
25 nitrogen atom of the indole ring by alkyl, haloalkyl,
26 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,

HB2534 Engrossed- 12 -LRB100 08419 RLC 18533 b
1 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl,
2 or 2-(4-morpholinyl)ethyl whether or not further
3 substituted in the indole ring to any extent, whether
4 or not substituted in the naphthyl ring to any extent.
5 Examples of this structural class include, but are
6 not limited to, JWH-018, AM-2201, JWH-175, JWH-184,
7 and JWH-185;
8 (43) Any compound structurally derived from
9 3-(1-naphthoyl)pyrrole by substitution at the nitrogen
10 atom of the pyrrole ring by alkyl, haloalkyl, alkenyl,
11 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl
12 aryl halide, 1-(N-methyl-2-piperidinyl)methyl,
13 or 2-(4-morpholinyl)ethyl, whether or not further
14 substituted in the pyrrole ring to any extent, whether
15 or not substituted in the naphthyl ring to any extent.
16 Examples of this structural class include, but are not
17 limited to, JWH-030, JWH-145, JWH-146, JWH-307, and
18 JWH-368;
19 (44) Any compound structurally derived from
20 1-(1-naphthylmethyl)indene by substitution
21 at the 3-position of the indene ring by alkyl, haloalkyl,
22 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
23 halide, alkyl aryl halide, 1-(N-methyl-
24 2-piperidinyl)methyl, or 2-(4-
25 morpholinyl)ethyl whether or not further substituted in
26 the indene ring to any extent, whether or not substituted

HB2534 Engrossed- 13 -LRB100 08419 RLC 18533 b
1 in the naphthyl ring to any extent. Examples of
2 this structural class include, but are not
3 limited to, JWH-176;
4 (45) Any compound structurally derived from
5 3-phenylacetylindole by substitution at the
6 nitrogen atom of the indole ring with alkyl, haloalkyl,
7 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
8 halide, alkyl aryl halide, 1-(N-methyl-2-
9 piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,
10 whether or not further substituted in the indole ring
11 to any extent, whether or not substituted in the phenyl
12 ring to any extent. Examples of this structural
13 class include, but are not limited to, JWH-167,
14 JWH-250, JWH-251, and RCS-8;
15 (46) Any compound structurally derived from
16 2-(3-hydroxycyclohexyl)phenol by substitution
17 at the 5-position of the phenolic ring by alkyl,
18 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
19 aryl halide, alkyl aryl halide, 1-(N-methyl-2-
20 piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,
21 whether or not substituted in the cyclohexyl ring to any
22 extent. Examples of this structural class
23 include, but are not limited to, CP 47,
24 497 and its C8 homologue (cannabicyclohexanol);
25 (46.1) Any compound structurally
26 derived from Benzoylindoles: Any compound

HB2534 Engrossed- 14 -LRB100 08419 RLC 18533 b
1 containing a 3-(benzoyl) indole structure with
2 substitution at the nitrogen atom of the
3 indole ring by an alkyl, haloalkyl, alkenyl,
4 cycloalkylmethyl, cycloalkylethyl,
5 aryl halide, alkyl aryl halide,
6 1-(N-methyl-2-piperidinyl)methyl,
7 or 2-(4-morpholinyl)ethyl group
8 whether or not further substituted
9 in the indole ring to any extent and
10 whether or not substituted in the phenyl ring
11 to any extent. Examples of this structural class
12 include, but are not limited, to, AM-630,
13 AM-2233, AM-694, Pravadoline (WIN 48,098), and RCS-4;
14 (47) (Blank); 3,4-Methylenedioxymethcathinone
15 Some trade or other names: Methylone;
16 (48) (Blank); 3,4-Methyenedioxypyrovalerone
17 Some trade or other names: MDPV;
18 (49) (Blank); 4-Methylmethcathinone
19 Some trade or other names: Mephedrone;
20 (50) (Blank); 4-methoxymethcathinone;
21 (51) (Blank); 4-Fluoromethcathinone;
22 (52) (Blank); 3-Fluoromethcathinone;
23 (53) 2,5-Dimethoxy-4-(n)-propylthio-
24 phenethylamine;
25 Some trade or other names: 2C-T-7;
26 (53.1) 4-ethyl-2,5-dimethoxyphenethylamine

HB2534 Engrossed- 15 -LRB100 08419 RLC 18533 b
1 Some trade or other names: 2C-E;
2 (53.2) 2,5-dimethoxy-4-methylphenethylamine
3 Some trade or other names: 2C-D;
4 (53.3) 4-chloro-2,5-dimethoxyphenethylamine
5 Some trade or other names: 2C-C;
6 (53.4) 4-iodo-2,5-dimethoxyphenethylamine
7 Some trade or other names: 2C-I;
8 (53.5) 4-ethylthio-2,5-dimethoxyphenethylamine
9 Some trade or other names: 2C-T-2;
10 (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine
11 Some trade or other names: 2C-T-4;
12 (53.7) 2,5-dimethoxyphenethylamine
13 Some trade or other names: 2C-H;
14 (53.8) 2,5-dimethoxy-4-nitrophenethylamine
15 Some trade or other names: 2C-N;
16 (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine
17 Some trade or other names: 2C-P;
18 (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine
19 Some trade or other names: 2C-G;
20 (53.11) The N-(2-methoxybenzyl) derivative of any 2C
21 phenethylamine referred to in subparagraphs (20.1), (53),
22 (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7),
23 (53.8), (53.9), and (53.10) including, but not limited to,
24 25I-NBOMe and 25C-NBOMe;
25 (54) 5-Methoxy-N,N-diisopropyltryptamine;
26 (55) (Blank); Pentedrone;

HB2534 Engrossed- 16 -LRB100 08419 RLC 18533 b
1 (56) (Blank); 4-iodo-2,5-dimethoxy-N-((2-methoxy
2 phenyl)methyl)-benzeneethanamine
3 (trade or other name: 25I-NBOMe);
4 (57) (Blank); 4-chloro-2,5-dimethoxy-
5 N-[(2-methoxyphenyl) methyl]-benzeneethanamine
6 (trade or other name: 25C-NBOMe);
7 (58) (Blank); 4-bromo-2,5-dimethoxy
8 -N-[(2-methoxyphenyl) methyl]-benzeneethanamine
9 (trade or other name: 25B-NBOMe);
10 (59) 3-cyclopropoylindole with
11 substitution at the nitrogen atom of the
12 indole ring by alkyl, haloalkyl, alkenyl,
13 cycloalkylmethyl, cycloalkylethyl, aryl
14 halide, alkyl aryl halide,
15 1-(N-methyl-2-piperidinyl)methyl, or
16 2-(4-morpholinyl)ethyl, whether or not
17 further substituted on the indole ring
18 to any extent, whether or not substituted
19 on the cyclopropyl ring to any extent:
20 including, but not limited to, XLR11,
21 UR144, FUB-144;
22 (60) 3-adamantoylindole with
23 substitution at the nitrogen atom of the
24 indole ring by alkyl, haloalkyl, alkenyl,
25 cycloalkylmethyl, cycloalkylethyl,
26 aryl halide, alkyl aryl halide,

HB2534 Engrossed- 17 -LRB100 08419 RLC 18533 b
1 1-(N-methyl-2-piperidinyl)methyl, or
2 2-(4-morpholinyl)ethyl, whether or not
3 further substituted on the indole ring to
4 any extent, whether or not substituted on
5 the adamantyl ring to any extent: including,
6 but not limited to, AB-001;
7 (61) N-(adamantyl)-indole-3-carboxamide
8 with substitution at the nitrogen atom of the
9 indole ring by alkyl, haloalkyl, alkenyl,
10 cycloalkylmethyl, cycloalkylethyl, aryl halide,
11 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl,
12 or 2-(4-morpholinyl)ethyl, whether or not further
13 substituted on the indole ring to any extent, whether
14 or not substituted on the adamantyl ring to any
15 extent: including, but not limited to,
16 APICA/2NE-1, STS-135;
17 (62) N-(adamantyl)-indazole-3-carboxamide
18 with substitution at a nitrogen atom of the indazole
19 ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
20 cycloalkylethyl, aryl halide, alkyl aryl halide,
21 1-(N-methyl-2-piperidinyl)methyl, or
22 2-(4-morpholinyl)ethyl, whether or not further
23 substituted on the indazole ring to any extent,
24 whether or not substituted on the adamantyl
25 ring to any extent: including, but not limited
26 to, AKB48, 5F-AKB48;

HB2534 Engrossed- 18 -LRB100 08419 RLC 18533 b
1 (63) 1H-indole-3-carboxylic acid 8-quinolinyl
2 ester with substitution at the nitrogen atom of the
3 indole ring by alkyl, haloalkyl, alkenyl,
4 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl
5 aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
6 2-(4-morpholinyl)ethyl, whether or not further
7 substituted on the indole ring to any extent,
8 whether or not substituted on the quinoline ring
9 to any extent: including, but not limited to, PB22,
10 5F-PB22, FUB-PB-22;
11 (64) 3-(1-naphthoyl)indazole with
12 substitution at the nitrogen atom of the
13 indazole ring by alkyl, haloalkyl,
14 alkenyl, cycloalkylmethyl, cycloalkylethyl,
15 aryl halide, alkyl aryl halide,
16 1-(N-methyl-2-piperidinyl)methyl, or
17 2-(4-morpholinyl)ethyl, whether or not further
18 substituted on the indazole ring to any extent,
19 whether or not substituted on the naphthyl ring
20 to any extent: including, but not limited to,
21 THJ-018, THJ-2201;
22 (65) 2-(1-naphthoyl)benzimidazole with
23 substitution at the nitrogen atom of the benzimidazole
24 ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
25 cycloalkylethyl, aryl halide, alkyl aryl halide,
26 1-(N-methyl-2-piperidinyl)methyl, or

HB2534 Engrossed- 19 -LRB100 08419 RLC 18533 b
1 2-(4-morpholinyl)ethyl, whether or not further
2 substituted on the benzimidazole ring to any extent,
3 whether or not substituted on the naphthyl ring to
4 any extent: including, but not limited to, FUBIMINA;
5 (66) N-(1-amino-3-methyl-1-oxobutan-2-yl)
6 -1H-indazole-3-carboxamide with substitution on the
7 nitrogen atom of the indazole ring by alkyl,
8 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
9 aryl halide, alkyl aryl halide, 1-(N-methyl-2-
10 piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,
11 whether or not further substituted on the indazole
12 ring to any extent: including, but not limited to,
13 AB-PINACA, AB-FUBINACA, AB-CHMINACA;
14 (67) N-(1-amino-3,3-dimethyl-1-oxobutan-
15 2-yl)-1H-indazole-3-carboxamide with substitution
16 on the nitrogen atom of the indazole ring by alkyl,
17 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
18 aryl halide, alkyl aryl halide, 1-(N-methyl-2-
19 piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether
20 or not further substituted on the indazole ring to any
21 extent: including, but not limited to, ADB-PINACA,
22ADB-FUBINACA;
23 (68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-
24 1H-indole-3-carboxamide with substitution on the nitrogen
25 atom of the indole ring by alkyl, haloalkyl, alkenyl,
26 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl

HB2534 Engrossed- 20 -LRB100 08419 RLC 18533 b
1 aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
2 2-(4-morpholinyl)ethyl, whether or not further
3 substituted on the indole ring to any extent:
4 including, but not limited to, ADBICA, 5F-ADBICA;
5 (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-
6 1H-indole-3-carboxamide with substitution on the
7 nitrogen atom of the indole ring by alkyl, haloalkyl,
8 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
9 halide, alkyl aryl halide, 1-(N-methyl-2-
10 piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,
11 whether or not further substituted on the indole
12 ring to any extent: including, but not limited
13 to, ABICA, 5F-ABICA;
14 (70) Methyl 2-(1H-indazole-3-carboxamido)-
15 3-methylbutanoate with substitution on the nitrogen
16 atom of the indazole ring by alkyl, haloalkyl,
17 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
18 halide, alkyl aryl halide, 1-(N-methyl-2-
19 piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,
20 whether or not further substituted on the indazole
21 ring to any extent: including, but not limited to, AMB,
225F-AMB.
23 (71) Methyl 2-(1H-indazole-3-carboxamido)
24 -3,3-dimethylbutanoate with substitution on the nitrogen
25 atom of the indazole ring by alkyl, haloalkyl, alkenyl,
26 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl

HB2534 Engrossed- 21 -LRB100 08419 RLC 18533 b
1 aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 2-
2 (4-morpholinyl)ethyl, whether or not further substituted
3 on the indazole ring to any extent: including, but not
4 limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA;
5 (72) Methyl 2-(1H-indole-3-carboxamido)-
6 3-methylbutanoate with substitution on the nitrogen atom
7 of the indole ring by alkyl, haloalkyl, alkenyl,
8 cycloalkylmethyl, cycloalkylethyl, aryl halide,
9 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl,
10 or 2-(4-morpholinyl)ethyl, whether or not further
11 substituted on the indazole ring to any extent:
12 including, but not limited to, MMB018, MMB2201,
13 and AMB-CHMICA;
14 (73) Methyl 2-(1H-indole-3-
15 carboxamido)-3,3-dimethylbutanoate with substitution
16 on the nitrogen atom of the indole ring by alkyl,
17 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
18 aryl halide, alkyl aryl halide, 1-(N-methyl-2-
19 piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,
20 whether or not further substituted on the
21 indazole ring to any extent: including, but
22 not limited to, MDMB-CHMICA;
23 (74) N-(1-Amino-1-oxo-3-phenylpropan
24 -2-yl) -1H-indazole-3-carboxamide with
25 substitution on the nitrogen atom of the indazole
26 ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,

HB2534 Engrossed- 22 -LRB100 08419 RLC 18533 b
1 cycloalkylethyl, aryl halide, alkyl aryl halide,
2 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-
3 morpholinyl)ethyl, whether or not further
4 substituted on the indazole ring to any
5 extent: including, but not limited to, APP-CHMINACA,
6 5-fluoro-APP-PINACA;
7 (75) N-(1-Amino-1-oxo-3-phenylpropan
8 -2-yl)-1H-indole-3-carboxamide with substitution on
9 the nitrogen atom of the indole ring by alkyl,
10 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
11 aryl halide, alkyl aryl halide, 1-(N-methyl-2-
12 piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,
13 whether or not further substituted on the indazole
14 ring to any extent: including, but not limited to,
15 APP-PICA and 5-fluoro-APP-PICA;
16 (76) 4-Acetoxy-N,N-dimethyltryptamine: trade name
17 4-AcO-DMT;
18 (77) 5-Methoxy-N-methyl-N-isopropyltryptamine: Trade
19 name 5-MeO-MIPT;
20 (78) 4-hydroxy Diethyltryptamine (4-HO-DET);
21 (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);
22 (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
23 (81) 4-hydroxy-N-methyl-N-isopropyltryptamine
24 (4-HO-MiPT);
25 (82) Fluorophenylpiperazine;
26 (83) Methoxetamine;

HB2534 Engrossed- 23 -LRB100 08419 RLC 18533 b
1 (84) 1-(Ethylamino)-2-phenylpropan-2-
2 one (iso-ethcathinone).
3 (e) Unless specifically excepted or unless listed in
4another schedule, any material, compound, mixture, or
5preparation which contains any quantity of the following
6substances having a depressant effect on the central nervous
7system, including its salts, isomers, and salts of isomers
8whenever the existence of such salts, isomers, and salts of
9isomers is possible within the specific chemical designation:
10 (1) mecloqualone;
11 (2) methaqualone; and
12 (3) gamma hydroxybutyric acid.
13 (f) Unless specifically excepted or unless listed in
14another schedule, any material, compound, mixture, or
15preparation which contains any quantity of the following
16substances having a stimulant effect on the central nervous
17system, including its salts, isomers, and salts of isomers:
18 (1) Fenethylline;
19 (2) N-ethylamphetamine;
20 (3) Aminorex (some other names:
21 2-amino-5-phenyl-2-oxazoline; aminoxaphen;
22 4-5-dihydro-5-phenyl-2-oxazolamine) and its
23 salts, optical isomers, and salts of optical isomers;
24 (4) Methcathinone (some other names:
25 2-methylamino-1-phenylpropan-1-one;
26 Ephedrone; 2-(methylamino)-propiophenone;

HB2534 Engrossed- 24 -LRB100 08419 RLC 18533 b
1 alpha-(methylamino)propiophenone; N-methylcathinone;
2 methycathinone; Monomethylpropion; UR 1431) and its
3 salts, optical isomers, and salts of optical isomers;
4 (5) Cathinone (some trade or other names:
5 2-aminopropiophenone; alpha-aminopropiophenone;
6 2-amino-1-phenyl-propanone; norephedrone);
7 (6) N,N-dimethylamphetamine (also known as:
8 N,N-alpha-trimethyl-benzeneethanamine;
9 N,N-alpha-trimethylphenethylamine);
10 (7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
11 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);
12 (8) 3,4-Methylenedioxypyrovalerone (MDPV); .
13 (9) Halogenated amphetamines and
14 methamphetamines any compound derived from either
15 amphetamine or methamphetamine through the substitution
16 of a halogen on the phenyl ring, including, but not
17 limited to, 2-fluoroamphetamine, 3-
18 fluoroamphetamine and 4-fluoroamphetamine;
19 (10) Aminopropylbenzofuran (APB):
20 including 4-(2-Aminopropyl) benzofuran, 5-
21 (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)
22 benzofuran, and 7-(2-Aminopropyl) benzofuran;
23 (11) Aminopropyldihydrobenzofuran (APDB):
24 including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,
25 5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,
26 6-(2-Aminopropyl)-2,3-dihydrobenzofuran,

HB2534 Engrossed- 25 -LRB100 08419 RLC 18533 b
1 and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran;
2 (12) Methylaminopropylbenzofuran
3 (MAPB): including 4-(2-methylaminopropyl)
4 benzofuran, 5-(2-methylaminopropyl)benzofuran,
5 6-(2-methylaminopropyl)benzofuran
6 and 7-(2-methylaminopropyl)benzofuran.
7 (g) Temporary listing of substances subject to emergency
8scheduling. Any material, compound, mixture, or preparation
9that contains any quantity of the following substances:
10 (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
11 (benzylfentanyl), its optical isomers, isomers, salts,
12 and salts of isomers;
13 (2) N-[1(2-thienyl)
14 methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl),
15 its optical isomers, salts, and salts of isomers.
16 (h) Synthetic cathinones. Unless specifically excepted,
17any chemical compound which is not approved by the United
18States Food and Drug Administration or, if approved, is not
19dispensed or possessed in accordance with State or federal law,
20not including bupropion, structurally derived from
212-aminopropan-1-one by substitution at the 1-position with
22either phenyl, naphthyl, or thiophene ring systems, whether or
23not the compound is further modified in one or more of the
24following ways:
25 (1) by substitution in the ring system to
26 any extent with alkyl, alkylenedioxy, alkoxy,

HB2534 Engrossed- 26 -LRB100 08419 RLC 18533 b
1 haloalkyl, hydroxyl, or halide substituents, whether
2 or not further substituted in the ring system
3 by one or more other univalent substituents.
4 Examples of this class include, but are not
5 limited to, 3,4-Methylenedioxycathinone
6 (bk-MDA);
7 (2) by substitution at the 3-position
8 with an acyclic alkyl substituent. Examples of
9 this class include, but are not limited to,
10 2-methylamino-1-phenylbutan-1-one
11 (buphedrone); or
12 (3) by substitution at the 2-amino nitrogen
13 atom with alkyl, dialkyl, benzyl, or methoxybenzyl
14 groups, or by inclusion of the 2-amino nitrogen atom
15 in a cyclic structure. Examples of this class include,
16 but are not limited to, Dimethylcathinone, Ethcathinone,
17 and a-Pyrrolidinopropiophenone (a-PPP).
18(Source: P.A. 98-987, eff. 1-1-15; 99-371, eff. 1-1-16; revised
1910-25-16.)
20 (720 ILCS 570/206) (from Ch. 56 1/2, par. 1206)
21 Sec. 206. (a) The controlled substances listed in this
22Section are included in Schedule II.
23 (b) Unless specifically excepted or unless listed in
24another schedule, any of the following substances whether
25produced directly or indirectly by extraction from substances

HB2534 Engrossed- 27 -LRB100 08419 RLC 18533 b
1of vegetable origin, or independently by means of chemical
2synthesis, or by combination of extraction and chemical
3synthesis:
4 (1) Opium and opiates, and any salt, compound,
5 derivative or preparation of opium or opiate, excluding
6 apomorphine, dextrorphan, levopropoxyphene, nalbuphine,
7 nalmefene, naloxone, and naltrexone, and their respective
8 salts, but including the following:
9 (i) Raw Opium;
10 (ii) Opium extracts;
11 (iii) Opium fluid extracts;
12 (iv) Powdered opium;
13 (v) Granulated opium;
14 (vi) Tincture of opium;
15 (vii) Codeine;
16 (viii) Ethylmorphine;
17 (ix) Etorphine Hydrochloride;
18 (x) Hydrocodone;
19 (xi) Hydromorphone;
20 (xii) Metopon;
21 (xiii) Morphine;
22 (xiii.5) 6-Monoacetylmorphine;
23 (xiv) Oxycodone;
24 (xv) Oxymorphone;
25 (xv.5) Tapentadol;
26 (xvi) Thebaine;

HB2534 Engrossed- 28 -LRB100 08419 RLC 18533 b
1 (xvii) Thebaine-derived butorphanol.
2 (xviii) Methorphan Dextromethorphan, except drug
3 products containing dextromethorphan that may be
4 dispensed pursuant to a prescription order of a
5 practitioner and are sold in compliance with the safety
6 and labeling standards as set forth by the United
7 States Food and Drug Administration, or drug products
8 containing dextromethorphan that are sold in solid,
9 tablet, liquid, capsule, powder, thin film, or gel form
10 and which are formulated, packaged, and sold in dosages
11 and concentrations for use as an over-the-counter drug
12 product. For the purposes of this Section,
13 "over-the-counter drug product" means a drug that is
14 available to consumers without a prescription and sold
15 in compliance with the safety and labeling standards as
16 set forth by the United States Food and Drug
17 Administration.
18 (2) Any salt, compound, isomer, derivative or
19 preparation thereof which is chemically equivalent or
20 identical with any of the substances referred to in
21 subparagraph (1), but not including the isoquinoline
22 alkaloids of opium;
23 (3) Opium poppy and poppy straw;
24 (4) Coca leaves and any salt, compound, isomer, salt of
25 an isomer, derivative, or preparation of coca leaves
26 including cocaine or ecgonine, and any salt, compound,

HB2534 Engrossed- 29 -LRB100 08419 RLC 18533 b
1 isomer, derivative, or preparation thereof which is
2 chemically equivalent or identical with any of these
3 substances, but not including decocainized coca leaves or
4 extractions of coca leaves which do not contain cocaine or
5 ecgonine (for the purpose of this paragraph, the term
6 "isomer" includes optical, positional and geometric
7 isomers);
8 (5) Concentrate of poppy straw (the crude extract of
9 poppy straw in either liquid, solid or powder form which
10 contains the phenanthrine alkaloids of the opium poppy).
11 (c) Unless specifically excepted or unless listed in
12another schedule any of the following opiates, including their
13isomers, esters, ethers, salts, and salts of isomers, whenever
14the existence of these isomers, esters, ethers and salts is
15possible within the specific chemical designation, dextrorphan
16excepted:
17 (1) Alfentanil;
18 (1.1) Carfentanil;
19 (1.2) Thiafentanyl;
20 (2) Alphaprodine;
21 (3) Anileridine;
22 (4) Bezitramide;
23 (5) Bulk Dextropropoxyphene (non-dosage forms);
24 (6) Dihydrocodeine;
25 (7) Diphenoxylate;
26 (8) Fentanyl;

HB2534 Engrossed- 30 -LRB100 08419 RLC 18533 b
1 (9) Sufentanil;
2 (9.5) Remifentanil;
3 (10) Isomethadone;
4 (11) (Blank); Levomethorphan;
5 (12) Levorphanol (Levorphan);
6 (13) Metazocine;
7 (14) Methadone;
8 (15) Methadone-Intermediate,
9 4-cyano-2-dimethylamino-4,4-diphenyl-1-butane;
10 (16) Moramide-Intermediate,
11 2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic
12 acid;
13 (17) Pethidine (meperidine);
14 (18) Pethidine-Intermediate-A,
15 4-cyano-1-methyl-4-phenylpiperidine;
16 (19) Pethidine-Intermediate-B,
17 ethyl-4-phenylpiperidine-4-carboxylate;
18 (20) Pethidine-Intermediate-C,
19 1-methyl-4-phenylpiperidine-4-carboxylic acid;
20 (21) Phenazocine;
21 (22) Piminodine;
22 (23) Racemethorphan;
23 (24) (Blank); Racemorphan;
24 (25) Levo-alphacetylmethadol (some other names:
25 levo-alpha-acetylmethadol, levomethadyl acetate, LAAM).
26 (d) Unless specifically excepted or unless listed in

HB2534 Engrossed- 31 -LRB100 08419 RLC 18533 b
1another schedule, any material, compound, mixture, or
2preparation which contains any quantity of the following
3substances having a stimulant effect on the central nervous
4system:
5 (1) Amphetamine, its salts, optical isomers, and salts
6 of its optical isomers;
7 (2) Methamphetamine, its salts, isomers, and salts of
8 its isomers;
9 (3) Phenmetrazine and its salts;
10 (4) Methylphenidate;
11 (5) Lisdexamfetamine.
12 (e) Unless specifically excepted or unless listed in
13another schedule, any material, compound, mixture, or
14preparation which contains any quantity of the following
15substances having a depressant effect on the central nervous
16system, including its salts, isomers, and salts of isomers
17whenever the existence of such salts, isomers, and salts of
18isomers is possible within the specific chemical designation:
19 (1) Amobarbital;
20 (2) Secobarbital;
21 (3) Pentobarbital;
22 (4) Pentazocine;
23 (5) Phencyclidine;
24 (6) Gluthethimide;
25 (7) (Blank).
26 (f) Unless specifically excepted or unless listed in

HB2534 Engrossed- 32 -LRB100 08419 RLC 18533 b
1another schedule, any material, compound, mixture, or
2preparation which contains any quantity of the following
3substances:
4 (1) Immediate precursor to amphetamine and
5 methamphetamine:
6 (i) Phenylacetone
7 Some trade or other names: phenyl-2-propanone;
8 P2P; benzyl methyl ketone; methyl benzyl ketone.
9 (2) Immediate precursors to phencyclidine:
10 (i) 1-phenylcyclohexylamine;
11 (ii) 1-piperidinocyclohexanecarbonitrile (PCC).
12 (3) Nabilone.
13(Source: P.A. 97-334, eff. 1-1-12.)
14 (720 ILCS 570/208) (from Ch. 56 1/2, par. 1208)
15 Sec. 208. (a) The controlled substances listed in this
16Section are included in Schedule III.
17 (b) Unless specifically excepted or unless listed in
18another schedule, any material, compound, mixture, or
19preparation which contains any quantity of the following
20substances having a stimulant effect on the central nervous
21system, including its salts, isomers (whether optical
22position, or geometric), and salts of such isomers whenever the
23existence of such salts, isomers, and salts of isomers is
24possible within the specific chemical designation;
25 (1) Those compounds, mixtures, or preparations in

HB2534 Engrossed- 33 -LRB100 08419 RLC 18533 b
1 dosage unit form containing any stimulant substances
2 listed in Schedule II which compounds, mixtures, or
3 preparations were listed on August 25, 1971, as excepted
4 compounds under Title 21, Code of Federal Regulations,
5 Section 308.32, and any other drug of the quantitative
6 composition shown in that list for those drugs or which is
7 the same except that it contains a lesser quantity of
8 controlled substances;
9 (2) Benzphetamine;
10 (3) Chlorphentermine;
11 (4) Clortermine;
12 (5) Phendimetrazine.
13 (c) Unless specifically excepted or unless listed in
14another schedule, any material, compound, mixture, or
15preparation which contains any quantity of the following
16substances having a potential for abuse associated with a
17depressant effect on the central nervous system:
18 (1) Any compound, mixture, or preparation containing
19 amobarbital, secobarbital, pentobarbital or any salt
20 thereof and one or more other active medicinal ingredients
21 which are not listed in any schedule;
22 (2) Any suppository dosage form containing
23 amobarbital, secobarbital, pentobarbital or any salt of
24 any of these drugs and approved by the Federal Food and
25 Drug Administration for marketing only as a suppository;
26 (3) Any substance which contains any quantity of a

HB2534 Engrossed- 34 -LRB100 08419 RLC 18533 b
1 derivative of barbituric acid, or any salt thereof:
2 (3.1) Aprobarbital;
3 (3.2) Butabarbital (secbutabarbital);
4 (3.3) Butalbital;
5 (3.4) Butobarbital (butethal);
6 (4) Chlorhexadol;
7 (5) Methyprylon;
8 (6) Sulfondiethylmethane;
9 (7) Sulfonethylmethane;
10 (8) Sulfonmethane;
11 (9) Lysergic acid;
12 (10) Lysergic acid amide;
13 (10.1) Tiletamine or zolazepam or both, or any salt of
14 either of them.
15 Some trade or other names for a tiletamine-zolazepam
16 combination product: Telazol.
17 Some trade or other names for Tiletamine:
18 2-(ethylamino)-2-(2-thienyl)-cyclohexanone.
19 Some trade or other names for zolazepam:
20 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-
21 [3,4-e], [1,4]-diazepin-7(1H)-one, and flupyrazapon.
22 (11) Any material, compound, mixture or preparation
23 containing not more than 12.5 milligrams of pentazocine or
24 any of its salts, per 325 milligrams of aspirin;
25 (12) Any material, compound, mixture or preparation
26 containing not more than 12.5 milligrams of pentazocine or

HB2534 Engrossed- 35 -LRB100 08419 RLC 18533 b
1 any of its salts, per 325 milligrams of acetaminophen;
2 (13) Any material, compound, mixture or preparation
3 containing not more than 50 milligrams of pentazocine or
4 any of its salts plus naloxone HCl USP 0.5 milligrams, per
5 dosage unit;
6 (14) Ketamine;
7 (15) Thiopental.
8 (d) Nalorphine.
9 (d.5) Buprenorphine.
10 (e) Unless specifically excepted or unless listed in
11another schedule, any material, compound, mixture, or
12preparation containing limited quantities of any of the
13following narcotic drugs, or their salts calculated as the free
14anhydrous base or alkaloid, as set forth below:
15 (1) not more than 1.8 grams of codeine per 100
16 milliliters or not more than 90 milligrams per dosage unit,
17 with an equal or greater quantity of an isoquinoline
18 alkaloid of opium;
19 (2) not more than 1.8 grams of codeine per 100
20 milliliters or not more than 90 milligrams per dosage unit,
21 with one or more active non-narcotic ingredients in
22 recognized therapeutic amounts;
23 (3) (blank); not more than 300 milligrams of
24 dihydrocodeinone per 100 milliliters or not more than 15
25 milligrams per dosage unit, with a fourfold or greater
26 quantity of an isoquinoline alkaloid of opium;

HB2534 Engrossed- 36 -LRB100 08419 RLC 18533 b
1 (4) (blank); not more than 300 milligrams of
2 dihydrocodeinone per 100 milliliters or not more than 15
3 milligrams per dosage unit, with one or more active,
4 non-narcotic ingredients in recognized therapeutic
5 amounts;
6 (5) not more than 1.8 grams of dihydrocodeine per 100
7 milliliters or not more than 90 milligrams per dosage unit,
8 with one or more active, non-narcotic ingredients in
9 recognized therapeutic amounts;
10 (6) not more than 300 milligrams of ethylmorphine per
11 100 milliliters or not more than 15 milligrams per dosage
12 unit, with one or more active, non-narcotic ingredients in
13 recognized therapeutic amounts;
14 (7) not more than 500 milligrams of opium per 100
15 milliliters or per 100 grams, or not more than 25
16 milligrams per dosage unit, with one or more active,
17 non-narcotic ingredients in recognized therapeutic
18 amounts;
19 (8) not more than 50 milligrams of morphine per 100
20 milliliters or per 100 grams with one or more active,
21 non-narcotic ingredients in recognized therapeutic
22 amounts.
23 (f) Anabolic steroids, except the following anabolic
24steroids that are exempt:
25 (1) Androgyn L.A.;
26 (2) Andro-Estro 90-4;

HB2534 Engrossed- 37 -LRB100 08419 RLC 18533 b
1 (3) depANDROGYN;
2 (4) DEPO-T.E.;
3 (5) depTESTROGEN;
4 (6) Duomone;
5 (7) DURATESTRIN;
6 (8) DUO-SPAN II;
7 (9) Estratest;
8 (10) Estratest H.S.;
9 (11) PAN ESTRA TEST;
10 (12) Premarin with Methyltestosterone;
11 (13) TEST-ESTRO Cypionates;
12 (14) Testosterone Cyp 50 Estradiol Cyp 2;
13 (15) Testosterone Cypionate-Estradiol Cypionate
14 injection; and
15 (16) Testosterone Enanthate-Estradiol Valerate
16 injection.
17 (g) Hallucinogenic substances.
18 (1) Dronabinol (synthetic) in sesame oil and
19 encapsulated in a soft gelatin capsule in a U.S. Food and
20 Drug Administration approved product. Some other names for
21 dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro-
22 6,6,9-trimethyl-3-pentyl-6H-dibenzo (b,d) pyran-1-ol) or
23 (-)-delta-9-(trans)-tetrahydrocannabinol.
24 (2) (Reserved).
25 (h) The Department may except by rule any compound,
26mixture, or preparation containing any stimulant or depressant

HB2534 Engrossed- 38 -LRB100 08419 RLC 18533 b
1substance listed in subsection (b) from the application of all
2or any part of this Act if the compound, mixture, or
3preparation contains one or more active medicinal ingredients
4not having a stimulant or depressant effect on the central
5nervous system, and if the admixtures are included therein in
6combinations, quantity, proportion, or concentration that
7vitiate the potential for abuse of the substances which have a
8stimulant or depressant effect on the central nervous system.
9(Source: P.A. 96-328, eff. 8-11-09; 96-1000, eff. 7-2-10;
1097-334, eff. 1-1-12.)
11 (720 ILCS 570/401) (from Ch. 56 1/2, par. 1401)
12 Sec. 401. Manufacture or delivery, or possession with
13intent to manufacture or deliver, a controlled substance, a
14counterfeit substance, or controlled substance analog. Except
15as authorized by this Act, it is unlawful for any person
16knowingly to manufacture or deliver, or possess with intent to
17manufacture or deliver, a controlled substance other than
18methamphetamine and other than bath salts as defined in the
19Bath Salts Prohibition Act sold or offered for sale in a retail
20mercantile establishment as defined in Section 16-0.1 of the
21Criminal Code of 2012, a counterfeit substance, or a controlled
22substance analog. A violation of this Act with respect to each
23of the controlled substances listed herein constitutes a single
24and separate violation of this Act. For purposes of this
25Section, "controlled substance analog" or "analog" means a

HB2534 Engrossed- 39 -LRB100 08419 RLC 18533 b
1substance, other than a controlled substance, which is not
2approved by the United States Food and Drug Administration or,
3if approved, is not dispensed or possessed in accordance with
4State or federal law, and that has a chemical structure
5substantially similar to that of a controlled substance in
6Schedule I or II, or that was specifically designed to produce
7an effect substantially similar to that of a controlled
8substance in Schedule I or II. Examples of chemical classes in
9which controlled substance analogs are found include, but are
10not limited to, the following: phenethylamines, N-substituted
11piperidines, morphinans, ecgonines, quinazolinones,
12substituted indoles, and arylcycloalkylamines. For purposes of
13this Act, a controlled substance analog shall be treated in the
14same manner as the controlled substance to which it is
15substantially similar.
16 (a) Any person who violates this Section with respect to
17the following amounts of controlled or counterfeit substances
18or controlled substance analogs, notwithstanding any of the
19provisions of subsections (c), (d), (e), (f), (g) or (h) to the
20contrary, is guilty of a Class X felony and shall be sentenced
21to a term of imprisonment as provided in this subsection (a)
22and fined as provided in subsection (b):
23 (1) (A) not less than 6 years and not more than 30
24 years with respect to 15 grams or more but less than
25 100 grams of a substance containing heroin, or an
26 analog thereof;

HB2534 Engrossed- 40 -LRB100 08419 RLC 18533 b
1 (B) not less than 9 years and not more than 40
2 years with respect to 100 grams or more but less than
3 400 grams of a substance containing heroin, or an
4 analog thereof;
5 (C) not less than 12 years and not more than 50
6 years with respect to 400 grams or more but less than
7 900 grams of a substance containing heroin, or an
8 analog thereof;
9 (D) not less than 15 years and not more than 60
10 years with respect to 900 grams or more of any
11 substance containing heroin, or an analog thereof;
12 (1.5) (A) not less than 6 years and not more than 30
13 years with respect to 15 grams or more but less than
14 100 grams of a substance containing fentanyl, or an
15 analog thereof;
16 (B) not less than 9 years and not more than 40
17 years with respect to 100 grams or more but less than
18 400 grams of a substance containing fentanyl, or an
19 analog thereof;
20 (C) not less than 12 years and not more than 50
21 years with respect to 400 grams or more but less than
22 900 grams of a substance containing fentanyl, or an
23 analog thereof;
24 (D) not less than 15 years and not more than 60
25 years with respect to 900 grams or more of a substance
26 containing fentanyl, or an analog thereof;

HB2534 Engrossed- 41 -LRB100 08419 RLC 18533 b
1 (2) (A) not less than 6 years and not more than 30
2 years with respect to 15 grams or more but less than
3 100 grams of a substance containing cocaine, or an
4 analog thereof;
5 (B) not less than 9 years and not more than 40
6 years with respect to 100 grams or more but less than
7 400 grams of a substance containing cocaine, or an
8 analog thereof;
9 (C) not less than 12 years and not more than 50
10 years with respect to 400 grams or more but less than
11 900 grams of a substance containing cocaine, or an
12 analog thereof;
13 (D) not less than 15 years and not more than 60
14 years with respect to 900 grams or more of any
15 substance containing cocaine, or an analog thereof;
16 (3) (A) not less than 6 years and not more than 30
17 years with respect to 15 grams or more but less than
18 100 grams of a substance containing morphine, or an
19 analog thereof;
20 (B) not less than 9 years and not more than 40
21 years with respect to 100 grams or more but less than
22 400 grams of a substance containing morphine, or an
23 analog thereof;
24 (C) not less than 12 years and not more than 50
25 years with respect to 400 grams or more but less than
26 900 grams of a substance containing morphine, or an

HB2534 Engrossed- 42 -LRB100 08419 RLC 18533 b
1 analog thereof;
2 (D) not less than 15 years and not more than 60
3 years with respect to 900 grams or more of a substance
4 containing morphine, or an analog thereof;
5 (4) 200 grams or more of any substance containing
6 peyote, or an analog thereof;
7 (5) 200 grams or more of any substance containing a
8 derivative of barbituric acid or any of the salts of a
9 derivative of barbituric acid, or an analog thereof;
10 (6) 200 grams or more of any substance containing
11 amphetamine or any salt of an optical isomer of
12 amphetamine, or an analog thereof;
13 (6.5) (blank);
14 (6.6) (blank);
15 (7) (A) not less than 6 years and not more than 30
16 years with respect to: (i) 15 grams or more but less
17 than 100 grams of a substance containing lysergic acid
18 diethylamide (LSD), or an analog thereof, or (ii) 15 or
19 more objects or 15 or more segregated parts of an
20 object or objects but less than 200 objects or 200
21 segregated parts of an object or objects containing in
22 them or having upon them any amounts of any substance
23 containing lysergic acid diethylamide (LSD), or an
24 analog thereof;
25 (B) not less than 9 years and not more than 40
26 years with respect to: (i) 100 grams or more but less

HB2534 Engrossed- 43 -LRB100 08419 RLC 18533 b
1 than 400 grams of a substance containing lysergic acid
2 diethylamide (LSD), or an analog thereof, or (ii) 200
3 or more objects or 200 or more segregated parts of an
4 object or objects but less than 600 objects or less
5 than 600 segregated parts of an object or objects
6 containing in them or having upon them any amount of
7 any substance containing lysergic acid diethylamide
8 (LSD), or an analog thereof;
9 (C) not less than 12 years and not more than 50
10 years with respect to: (i) 400 grams or more but less
11 than 900 grams of a substance containing lysergic acid
12 diethylamide (LSD), or an analog thereof, or (ii) 600
13 or more objects or 600 or more segregated parts of an
14 object or objects but less than 1500 objects or 1500
15 segregated parts of an object or objects containing in
16 them or having upon them any amount of any substance
17 containing lysergic acid diethylamide (LSD), or an
18 analog thereof;
19 (D) not less than 15 years and not more than 60
20 years with respect to: (i) 900 grams or more of any
21 substance containing lysergic acid diethylamide (LSD),
22 or an analog thereof, or (ii) 1500 or more objects or
23 1500 or more segregated parts of an object or objects
24 containing in them or having upon them any amount of a
25 substance containing lysergic acid diethylamide (LSD),
26 or an analog thereof;

HB2534 Engrossed- 44 -LRB100 08419 RLC 18533 b
1 (7.5) (A) not less than 6 years and not more than 30
2 years with respect to: (i) 15 grams or more but less
3 than 100 grams of a substance listed in paragraph (1),
4 (2), (2.1), (2.2), (3), (14.1), (19), (20), (20.1),
5 (21), (25), or (26) of subsection (d) of Section 204,
6 or an analog or derivative thereof, or (ii) 15 or more
7 pills, tablets, caplets, capsules, or objects but less
8 than 200 pills, tablets, caplets, capsules, or objects
9 containing in them or having upon them any amounts of
10 any substance listed in paragraph (1), (2), (2.1),
11 (2.2), (3), (14.1), (19), (20), (20.1), (21), (25), or
12 (26) of subsection (d) of Section 204, or an analog or
13 derivative thereof;
14 (B) not less than 9 years and not more than 40
15 years with respect to: (i) 100 grams or more but less
16 than 400 grams of a substance listed in paragraph (1),
17 (2), (2.1), (2.2), (3), (14.1), (19), (20), (20.1),
18 (21), (25), or (26) of subsection (d) of Section 204,
19 or an analog or derivative thereof, or (ii) 200 or more
20 pills, tablets, caplets, capsules, or objects but less
21 than 600 pills, tablets, caplets, capsules, or objects
22 containing in them or having upon them any amount of
23 any substance listed in paragraph (1), (2), (2.1),
24 (2.2), (3), (14.1), (19), (20), (20.1), (21), (25), or
25 (26) of subsection (d) of Section 204, or an analog or
26 derivative thereof;

HB2534 Engrossed- 45 -LRB100 08419 RLC 18533 b
1 (C) not less than 12 years and not more than 50
2 years with respect to: (i) 400 grams or more but less
3 than 900 grams of a substance listed in paragraph (1),
4 (2), (2.1), (2.2), (3), (14.1), (19), (20), (20.1),
5 (21), (25), or (26) of subsection (d) of Section 204,
6 or an analog or derivative thereof, or (ii) 600 or more
7 pills, tablets, caplets, capsules, or objects but less
8 than 1,500 pills, tablets, caplets, capsules, or
9 objects containing in them or having upon them any
10 amount of any substance listed in paragraph (1), (2),
11 (2.1), (2.2), (3), (14.1), (19), (20), (20.1), (21),
12 (25), or (26) of subsection (d) of Section 204, or an
13 analog or derivative thereof;
14 (D) not less than 15 years and not more than 60
15 years with respect to: (i) 900 grams or more of any
16 substance listed in paragraph (1), (2), (2.1), (2.2),
17 (3), (14.1), (19), (20), (20.1), (21), (25), or (26) of
18 subsection (d) of Section 204, or an analog or
19 derivative thereof, or (ii) 1,500 or more pills,
20 tablets, caplets, capsules, or objects containing in
21 them or having upon them any amount of a substance
22 listed in paragraph (1), (2), (2.1), (2.2), (3),
23 (14.1), (19), (20), (20.1), (21), (25), or (26) of
24 subsection (d) of Section 204, or an analog or
25 derivative thereof;
26 (8) 30 grams or more of any substance containing

HB2534 Engrossed- 46 -LRB100 08419 RLC 18533 b
1 pentazocine or any of the salts, isomers and salts of
2 isomers of pentazocine, or an analog thereof;
3 (9) 30 grams or more of any substance containing
4 methaqualone or any of the salts, isomers and salts of
5 isomers of methaqualone, or an analog thereof;
6 (10) 30 grams or more of any substance containing
7 phencyclidine or any of the salts, isomers and salts of
8 isomers of phencyclidine (PCP), or an analog thereof;
9 (10.5) 30 grams or more of any substance containing
10 ketamine or any of the salts, isomers and salts of isomers
11 of ketamine, or an analog thereof;
12 (10.6) 100 grams or more of any substance containing
13 hydrocodone, or any of the salts, isomers and salts of
14 isomers of hydrocodone, or an analog thereof;
15 (10.7) (blank); 100 grams or more of any substance
16 containing dihydrocodeinone, or any of the salts, isomers
17 and salts of isomers of dihydrocodeinone, or an analog
18 thereof;
19 (10.8) 100 grams or more of any substance containing
20 dihydrocodeine, or any of the salts, isomers and salts of
21 isomers of dihydrocodeine, or an analog thereof;
22 (10.9) 100 grams or more of any substance containing
23 oxycodone, or any of the salts, isomers and salts of
24 isomers of oxycodone, or an analog thereof;
25 (11) 200 grams or more of any substance containing any
26 other controlled substance classified in Schedules I or II,

HB2534 Engrossed- 47 -LRB100 08419 RLC 18533 b
1 or an analog thereof, which is not otherwise included in
2 this subsection.
3 (b) Any person sentenced with respect to violations of
4paragraph (1), (2), (3), (7), or (7.5) of subsection (a)
5involving 100 grams or more of the controlled substance named
6therein, may in addition to the penalties provided therein, be
7fined an amount not more than $500,000 or the full street value
8of the controlled or counterfeit substance or controlled
9substance analog, whichever is greater. The term "street value"
10shall have the meaning ascribed in Section 110-5 of the Code of
11Criminal Procedure of 1963. Any person sentenced with respect
12to any other provision of subsection (a), may in addition to
13the penalties provided therein, be fined an amount not to
14exceed $500,000.
15 (b-1) Excluding violations of this Act when the controlled
16substance is fentanyl, any person sentenced to a term of
17imprisonment with respect to violations of Section 401, 401.1,
18405, 405.1, 405.2, or 407, when the substance containing the
19controlled substance contains any amount of fentanyl, 3 years
20shall be added to the term of imprisonment imposed by the
21court, and the maximum sentence for the offense shall be
22increased by 3 years.
23 (c) Any person who violates this Section with regard to the
24following amounts of controlled or counterfeit substances or
25controlled substance analogs, notwithstanding any of the
26provisions of subsections (a), (b), (d), (e), (f), (g) or (h)

HB2534 Engrossed- 48 -LRB100 08419 RLC 18533 b
1to the contrary, is guilty of a Class 1 felony. The fine for
2violation of this subsection (c) shall not be more than
3$250,000:
4 (1) 1 gram or more but less than 15 grams of any
5 substance containing heroin, or an analog thereof;
6 (1.5) 1 gram or more but less than 15 grams of any
7 substance containing fentanyl, or an analog thereof;
8 (2) 1 gram or more but less than 15 grams of any
9 substance containing cocaine, or an analog thereof;
10 (3) 10 grams or more but less than 15 grams of any
11 substance containing morphine, or an analog thereof;
12 (4) 50 grams or more but less than 200 grams of any
13 substance containing peyote, or an analog thereof;
14 (5) 50 grams or more but less than 200 grams of any
15 substance containing a derivative of barbituric acid or any
16 of the salts of a derivative of barbituric acid, or an
17 analog thereof;
18 (6) 50 grams or more but less than 200 grams of any
19 substance containing amphetamine or any salt of an optical
20 isomer of amphetamine, or an analog thereof;
21 (6.5) (blank);
22 (7) (i) 5 grams or more but less than 15 grams of any
23 substance containing lysergic acid diethylamide (LSD), or
24 an analog thereof, or (ii) more than 10 objects or more
25 than 10 segregated parts of an object or objects but less
26 than 15 objects or less than 15 segregated parts of an

HB2534 Engrossed- 49 -LRB100 08419 RLC 18533 b
1 object containing in them or having upon them any amount of
2 any substance containing lysergic acid diethylamide (LSD),
3 or an analog thereof;
4 (7.5) (i) 5 grams or more but less than 15 grams of any
5 substance listed in paragraph (1), (2), (2.1), (2.2), (3),
6 (14.1), (19), (20), (20.1), (21), (25), or (26) of
7 subsection (d) of Section 204, or an analog or derivative
8 thereof, or (ii) more than 10 pills, tablets, caplets,
9 capsules, or objects but less than 15 pills, tablets,
10 caplets, capsules, or objects containing in them or having
11 upon them any amount of any substance listed in paragraph
12 (1), (2), (2.1), (2.2), (3), (14.1), (19), (20), (20.1),
13 (21), (25), or (26) of subsection (d) of Section 204, or an
14 analog or derivative thereof;
15 (8) 10 grams or more but less than 30 grams of any
16 substance containing pentazocine or any of the salts,
17 isomers and salts of isomers of pentazocine, or an analog
18 thereof;
19 (9) 10 grams or more but less than 30 grams of any
20 substance containing methaqualone or any of the salts,
21 isomers and salts of isomers of methaqualone, or an analog
22 thereof;
23 (10) 10 grams or more but less than 30 grams of any
24 substance containing phencyclidine or any of the salts,
25 isomers and salts of isomers of phencyclidine (PCP), or an
26 analog thereof;

HB2534 Engrossed- 50 -LRB100 08419 RLC 18533 b
1 (10.5) 10 grams or more but less than 30 grams of any
2 substance containing ketamine or any of the salts, isomers
3 and salts of isomers of ketamine, or an analog thereof;
4 (10.6) 50 grams or more but less than 100 grams of any
5 substance containing hydrocodone, or any of the salts,
6 isomers and salts of isomers of hydrocodone, or an analog
7 thereof;
8 (10.7) (blank); 50 grams or more but less than 100
9 grams of any substance containing dihydrocodeinone, or any
10 of the salts, isomers and salts of isomers of
11 dihydrocodeinone, or an analog thereof;
12 (10.8) 50 grams or more but less than 100 grams of any
13 substance containing dihydrocodeine, or any of the salts,
14 isomers and salts of isomers of dihydrocodeine, or an
15 analog thereof;
16 (10.9) 50 grams or more but less than 100 grams of any
17 substance containing oxycodone, or any of the salts,
18 isomers and salts of isomers of oxycodone, or an analog
19 thereof;
20 (11) 50 grams or more but less than 200 grams of any
21 substance containing a substance classified in Schedules I
22 or II, or an analog thereof, which is not otherwise
23 included in this subsection.
24 (c-5) (Blank).
25 (d) Any person who violates this Section with regard to any
26other amount of a controlled or counterfeit substance

HB2534 Engrossed- 51 -LRB100 08419 RLC 18533 b
1containing dihydrocodeinone or dihydrocodeine or classified in
2Schedules I or II, or an analog thereof, which is (i) a
3narcotic drug, (ii) lysergic acid diethylamide (LSD) or an
4analog thereof, (iii) any substance containing amphetamine or
5fentanyl or any salt or optical isomer of amphetamine or
6fentanyl, or an analog thereof, or (iv) any substance
7containing N-Benzylpiperazine (BZP) or any salt or optical
8isomer of N-Benzylpiperazine (BZP), or an analog thereof, is
9guilty of a Class 2 felony. The fine for violation of this
10subsection (d) shall not be more than $200,000.
11 (d-5) (Blank).
12 (e) Any person who violates this Section with regard to any
13other amount of a controlled substance other than
14methamphetamine or counterfeit substance classified in
15Schedule I or II, or an analog thereof, which substance is not
16included under subsection (d) of this Section, is guilty of a
17Class 3 felony. The fine for violation of this subsection (e)
18shall not be more than $150,000.
19 (f) Any person who violates this Section with regard to any
20other amount of a controlled or counterfeit substance
21classified in Schedule III is guilty of a Class 3 felony. The
22fine for violation of this subsection (f) shall not be more
23than $125,000.
24 (g) Any person who violates this Section with regard to any
25other amount of a controlled or counterfeit substance
26classified in Schedule IV is guilty of a Class 3 felony. The

HB2534 Engrossed- 52 -LRB100 08419 RLC 18533 b
1fine for violation of this subsection (g) shall not be more
2than $100,000.
3 (h) Any person who violates this Section with regard to any
4other amount of a controlled or counterfeit substance
5classified in Schedule V is guilty of a Class 3 felony. The
6fine for violation of this subsection (h) shall not be more
7than $75,000.
8 (i) This Section does not apply to the manufacture,
9possession or distribution of a substance in conformance with
10the provisions of an approved new drug application or an
11exemption for investigational use within the meaning of Section
12505 of the Federal Food, Drug and Cosmetic Act.
13 (j) (Blank).
14(Source: P.A. 99-371, eff. 1-1-16; 99-585, eff. 1-1-17.)
15 (720 ILCS 570/402) (from Ch. 56 1/2, par. 1402)
16 Sec. 402. Except as otherwise authorized by this Act, it is
17unlawful for any person knowingly to possess a controlled or
18counterfeit substance or controlled substance analog. A
19violation of this Act with respect to each of the controlled
20substances listed herein constitutes a single and separate
21violation of this Act. For purposes of this Section,
22"controlled substance analog" or "analog" means a substance,
23other than a controlled substance, which is not approved by the
24United States Food and Drug Administration or, if approved, is
25not dispensed or possessed in accordance with State or federal

HB2534 Engrossed- 53 -LRB100 08419 RLC 18533 b
1law, and that has a chemical structure substantially similar to
2that of a controlled substance in Schedule I or II, or that was
3specifically designed to produce an effect substantially
4similar to that of a controlled substance in Schedule I or II.
5Examples of chemical classes in which controlled substance
6analogs are found include, but are not limited to, the
7following: phenethylamines, N-substituted piperidines,
8morphinans, ecgonines, quinazolinones, substituted indoles,
9and arylcycloalkylamines. For purposes of this Act, a
10controlled substance analog shall be treated in the same manner
11as the controlled substance to which it is substantially
12similar.
13 (a) Any person who violates this Section with respect to
14the following controlled or counterfeit substances and
15amounts, notwithstanding any of the provisions of subsections
16(c) and (d) to the contrary, is guilty of a Class 1 felony and
17shall, if sentenced to a term of imprisonment, be sentenced as
18provided in this subsection (a) and fined as provided in
19subsection (b):
20 (1) (A) not less than 4 years and not more than 15
21 years with respect to 15 grams or more but less than
22 100 grams of a substance containing heroin;
23 (B) not less than 6 years and not more than 30
24 years with respect to 100 grams or more but less than
25 400 grams of a substance containing heroin;
26 (C) not less than 8 years and not more than 40

HB2534 Engrossed- 54 -LRB100 08419 RLC 18533 b
1 years with respect to 400 grams or more but less than
2 900 grams of any substance containing heroin;
3 (D) not less than 10 years and not more than 50
4 years with respect to 900 grams or more of any
5 substance containing heroin;
6 (2) (A) not less than 4 years and not more than 15
7 years with respect to 15 grams or more but less than
8 100 grams of any substance containing cocaine;
9 (B) not less than 6 years and not more than 30
10 years with respect to 100 grams or more but less than
11 400 grams of any substance containing cocaine;
12 (C) not less than 8 years and not more than 40
13 years with respect to 400 grams or more but less than
14 900 grams of any substance containing cocaine;
15 (D) not less than 10 years and not more than 50
16 years with respect to 900 grams or more of any
17 substance containing cocaine;
18 (3) (A) not less than 4 years and not more than 15
19 years with respect to 15 grams or more but less than
20 100 grams of any substance containing morphine;
21 (B) not less than 6 years and not more than 30
22 years with respect to 100 grams or more but less than
23 400 grams of any substance containing morphine;
24 (C) not less than 6 years and not more than 40
25 years with respect to 400 grams or more but less than
26 900 grams of any substance containing morphine;

HB2534 Engrossed- 55 -LRB100 08419 RLC 18533 b
1 (D) not less than 10 years and not more than 50
2 years with respect to 900 grams or more of any
3 substance containing morphine;
4 (4) 200 grams or more of any substance containing
5 peyote;
6 (5) 200 grams or more of any substance containing a
7 derivative of barbituric acid or any of the salts of a
8 derivative of barbituric acid;
9 (6) 200 grams or more of any substance containing
10 amphetamine or any salt of an optical isomer of
11 amphetamine;
12 (6.5) (blank);
13 (7) (A) not less than 4 years and not more than 15
14 years with respect to: (i) 15 grams or more but less
15 than 100 grams of any substance containing lysergic
16 acid diethylamide (LSD), or an analog thereof, or (ii)
17 15 or more objects or 15 or more segregated parts of an
18 object or objects but less than 200 objects or 200
19 segregated parts of an object or objects containing in
20 them or having upon them any amount of any substance
21 containing lysergic acid diethylamide (LSD), or an
22 analog thereof;
23 (B) not less than 6 years and not more than 30
24 years with respect to: (i) 100 grams or more but less
25 than 400 grams of any substance containing lysergic
26 acid diethylamide (LSD), or an analog thereof, or (ii)

HB2534 Engrossed- 56 -LRB100 08419 RLC 18533 b
1 200 or more objects or 200 or more segregated parts of
2 an object or objects but less than 600 objects or less
3 than 600 segregated parts of an object or objects
4 containing in them or having upon them any amount of
5 any substance containing lysergic acid diethylamide
6 (LSD), or an analog thereof;
7 (C) not less than 8 years and not more than 40
8 years with respect to: (i) 400 grams or more but less
9 than 900 grams of any substance containing lysergic
10 acid diethylamide (LSD), or an analog thereof, or (ii)
11 600 or more objects or 600 or more segregated parts of
12 an object or objects but less than 1500 objects or 1500
13 segregated parts of an object or objects containing in
14 them or having upon them any amount of any substance
15 containing lysergic acid diethylamide (LSD), or an
16 analog thereof;
17 (D) not less than 10 years and not more than 50
18 years with respect to: (i) 900 grams or more of any
19 substance containing lysergic acid diethylamide (LSD),
20 or an analog thereof, or (ii) 1500 or more objects or
21 1500 or more segregated parts of an object or objects
22 containing in them or having upon them any amount of a
23 substance containing lysergic acid diethylamide (LSD),
24 or an analog thereof;
25 (7.5) (A) not less than 4 years and not more than 15
26 years with respect to: (i) 15 grams or more but less

HB2534 Engrossed- 57 -LRB100 08419 RLC 18533 b
1 than 100 grams of any substance listed in paragraph
2 (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
3 (20.1), (21), (25), or (26) of subsection (d) of
4 Section 204, or an analog or derivative thereof, or
5 (ii) 15 or more pills, tablets, caplets, capsules, or
6 objects but less than 200 pills, tablets, caplets,
7 capsules, or objects containing in them or having upon
8 them any amount of any substance listed in paragraph
9 (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
10 (20.1), (21), (25), or (26) of subsection (d) of
11 Section 204, or an analog or derivative thereof;
12 (B) not less than 6 years and not more than 30
13 years with respect to: (i) 100 grams or more but less
14 than 400 grams of any substance listed in paragraph
15 (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
16 (20.1), (21), (25), or (26) of subsection (d) of
17 Section 204, or an analog or derivative thereof, or
18 (ii) 200 or more pills, tablets, caplets, capsules, or
19 objects but less than 600 pills, tablets, caplets,
20 capsules, or objects containing in them or having upon
21 them any amount of any substance listed in paragraph
22 (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
23 (20.1), (21), (25), or (26) of subsection (d) of
24 Section 204, or an analog or derivative thereof;
25 (C) not less than 8 years and not more than 40
26 years with respect to: (i) 400 grams or more but less

HB2534 Engrossed- 58 -LRB100 08419 RLC 18533 b
1 than 900 grams of any substance listed in paragraph
2 (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
3 (20.1), (21), (25), or (26) of subsection (d) of
4 Section 204, or an analog or derivative thereof, or
5 (ii) 600 or more pills, tablets, caplets, capsules, or
6 objects but less than 1,500 pills, tablets, caplets,
7 capsules, or objects containing in them or having upon
8 them any amount of any substance listed in paragraph
9 (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
10 (20.1), (21), (25), or (26) of subsection (d) of
11 Section 204, or an analog or derivative thereof;
12 (D) not less than 10 years and not more than 50
13 years with respect to: (i) 900 grams or more of any
14 substance listed in paragraph (1), (2), (2.1), (2.2),
15 (3), (14.1), (19), (20), (20.1), (21), (25), or (26) of
16 subsection (d) of Section 204, or an analog or
17 derivative thereof, or (ii) 1,500 or more pills,
18 tablets, caplets, capsules, or objects containing in
19 them or having upon them any amount of a substance
20 listed in paragraph (1), (2), (2.1), (2.2), (3),
21 (14.1), (19), (20), (20.1), (21), (25), or (26) of
22 subsection (d) of Section 204, or an analog or
23 derivative thereof;
24 (8) 30 grams or more of any substance containing
25 pentazocine or any of the salts, isomers and salts of
26 isomers of pentazocine, or an analog thereof;

HB2534 Engrossed- 59 -LRB100 08419 RLC 18533 b
1 (9) 30 grams or more of any substance containing
2 methaqualone or any of the salts, isomers and salts of
3 isomers of methaqualone;
4 (10) 30 grams or more of any substance containing
5 phencyclidine or any of the salts, isomers and salts of
6 isomers of phencyclidine (PCP);
7 (10.5) 30 grams or more of any substance containing
8 ketamine or any of the salts, isomers and salts of isomers
9 of ketamine;
10 (11) 200 grams or more of any substance containing any
11 substance classified as a narcotic drug in Schedules I or
12 II, or an analog thereof, which is not otherwise included
13 in this subsection.
14 (b) Any person sentenced with respect to violations of
15paragraph (1), (2), (3), (7), or (7.5) of subsection (a)
16involving 100 grams or more of the controlled substance named
17therein, may in addition to the penalties provided therein, be
18fined an amount not to exceed $200,000 or the full street value
19of the controlled or counterfeit substances, whichever is
20greater. The term "street value" shall have the meaning
21ascribed in Section 110-5 of the Code of Criminal Procedure of
221963. Any person sentenced with respect to any other provision
23of subsection (a), may in addition to the penalties provided
24therein, be fined an amount not to exceed $200,000.
25 (c) Any person who violates this Section with regard to an
26amount of a controlled substance other than methamphetamine or

HB2534 Engrossed- 60 -LRB100 08419 RLC 18533 b
1counterfeit substance not set forth in subsection (a) or (d) is
2guilty of a Class 4 felony. The fine for a violation punishable
3under this subsection (c) shall not be more than $25,000.
4 (d) Any person who violates this Section with regard to any
5amount of anabolic steroid is guilty of a Class C misdemeanor
6for the first offense and a Class B misdemeanor for a
7subsequent offense committed within 2 years of a prior
8conviction.
9(Source: P.A. 99-371, eff. 1-1-16.)
feedback